Drugs / Indium-111 ibritumomab tiuxetan
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00477815 | May 2005 → Jul 2011 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01207765 | Apr 2008 → Jan 2013 | plasma cell myeloma | Tufts Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT00070018 | Feb 2004 → Nov 2010 | lymphoma | SWOG Cancer Research Network | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | indium-111-ibritumomab tiuxetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01207765 ↗ |
| Known as | 111In Zevalin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00477815 ↗ |
| Action | Deplete | “designed to kill more multiple myeloma cells” NCT01207765 ↗ |
| Modality | Protein / enzyme biologic | “radiolabeled antibody” NCT01207765 ↗ |
| Route | Intravenous | “indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1” NCT00070018 ↗ |